To evaluate the effect of romosozumab followed by alendronate on lumbar spine aBMD and TBS in postmenopausal women with osteoporosis and type 2 diabetes.
Key Findings:
Romosozumab led to significantly greater gains in LS aBMD and TBSTT at month 12 compared to alendronate (p < 0.05).
Gains from romosozumab were maintained after transitioning to alendronate and persisted significantly at months 24 and 36 (p < 0.05).
TBSTT percentage changes weakly correlated with LS aBMD percentage changes from baseline to month 36 (R2 = 0.1493).
Interpretation:
In postmenopausal women with osteoporosis and type 2 diabetes, romosozumab followed by alendronate significantly improved LS aBMD and TBSTT, indicating potential enhancement of bone strength independent of abdominal fat, which may influence treatment strategies for osteoporosis.
Limitations:
Post hoc analysis may introduce bias and limit generalizability; further studies are needed to confirm findings.
The study only included women with a history of diabetes, limiting applicability to broader populations and other demographics.
Conclusion:
Romosozumab may improve bone strength in patients with type 2 diabetes, suggesting a beneficial treatment strategy for osteoporosis in this population.
Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.
Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.
